NEWS & ANALYSIS · HEALTHCARE INVESTOR MAGAZINE

UK Healthcare Investment News

Independent reporting on M&A deals, funding rounds, regulatory developments and market intelligence across UK healthcare — covering alternative healthcare investments, specialty pharma, medical cannabis, life sciences and all nine healthcare sectors.

BROWSE BY TAG:

Snoop Dogg's Casa Verde Capital Backs UK Medical Cannabis Clinic Mamedica with £4.5m

Simon Jones, Deputy Editor · June 2026

US-based venture capital firm Casa Verde Capital, co-founded by rapper Snoop Dogg, has invested £4.5 million in Mamedica — the UK's leading medical cannabis clinic — in the largest fundraising in the UK medical cannabis and alternative healthcare investment sector to date.

Read the full story →

NEWS · ALTERNATIVE HEALTHCARE INVESTMENTS

EXTERNAL →

Alternative Healthcare InvestmentsPrivate EquityLife Sciences

British Business Bank and Apposite Capital Launch £100m MedTech and Medicines Fund

Source: Med-Tech Insights · April 2026

The British Business Bank has committed cornerstone capital to a new £100 million fund called Apposite Healthcare Growth I, managed by Apposite Capital, a specialist healthcare and life sciences investor. The fund will invest in innovative UK companies across medical products, diagnostics, life sciences tools, digital health and pharmaceutical outsourcing services — addressing the shortage of scale-up capital for UK life sciences companies approaching a growth inflection point.

Read at Med-Tech Insights →

NEWS · SPECIALTY PHARMA

EXTERNAL →

Specialty PharmaM&ALife Sciences

US-UK Pharma Trade Deal Secures Zero Tariffs on UK Drug Exports for Three Years

Source: Osborne Clarke · April 2026

The US and UK governments announced a landmark deal on pharmaceutical trade and pricing on 2 April 2026, securing zero tariffs on UK pharmaceutical exports for at least three years. The agreement — building on the US-UK Economic Prosperity Deal agreed in May 2025 — also includes structural reforms to NHS medicines pricing and NICE evaluation aimed at improving patient access to medicines, and a pathway toward regulatory alignment for medical devices. It forms part of the UK government's life sciences sector plan, backed by over £2 billion of investment.

Read at Osborne Clarke →

NEWS · MEDICAL CANNABIS

EXTERNAL →

Medical CannabisAlternative Healthcare Investments

UK Medical Cannabis Market Approaching £1bn Valuation as Patient Numbers Near 100,000

Source: London Business Magazine · January 2026

The UK medical cannabis sector is expected to grow around 10% per year over the next five years. Patient numbers are approaching 100,000 — with the sector remaining far below its potential given that only 0.01–0.02% of UK residents have tried a medical cannabis prescription compared to 1–2% in comparable markets including Germany, the US and Canada. The first UK medical cannabis grower licensed to supply clinics for direct patient treatment began doing so in 2025, and investment into UK clinics and cultivation infrastructure accelerated throughout the year.

Read at London Business Magazine →

NEWS · VENTURE CAPITAL

EXTERNAL →

Venture CapitalLife Sciences

UK Biotech VC Rises 17% to £516m in Q1 2026 as Deal Count Jumps 60% Year-on-Year

Source: BIA (BioIndustry Association) · April 2026

UK biotech companies raised £516 million in venture capital in Q1 2026, representing a 17% increase from £442 million in Q4 2025. Deal activity rose to 24 transactions — up 60% from 15 deals in Q1 2025 — indicating a broader, more distributed funding environment compared to the large-round concentration of Q1 2025. The largest raise of the quarter was by Avacta Life Sciences, which secured £10 million to advance its clinical pipeline including oncology programmes. The increase was accompanied by broader distribution of investment across funding stages, signalling a more active and diversified environment for UK biotechs.

Read at BIA →

NEWS · PRIVATE EQUITY

EXTERNAL →

Private EquityM&A

UK Healthcare and Pharma Services M&A Surges 37% in Q1 2026 — PE Deals Up 43%

Source: Grant Thornton UK · Spring 2026

UK healthcare and pharma services M&A recorded 114 deals in Q1 2026 — a 37% uplift on the same period in 2025 — according to Grant Thornton's Spring 2026 review. Private equity and venture capital-backed transactions rose 43% year-on-year, driven by the sector's defensive resilience and structural growth characteristics. Key themes included diversification away from NHS dependency, continued appetite for niche specialist assets commanding high multiples, and PE interest in listed healthcare companies. Deals spanned medtech, pharma services, clinical services and social care.

Read at Grant Thornton →

NEWS · LIFE SCIENCES

EXTERNAL →

Life SciencesM&A

Eli Lilly Acquires UK Neuroscience Company Centessa Pharmaceuticals for Up to $7.8bn

Source: HealthCare MEA · April 2026

Eli Lilly has agreed to acquire UK-based neuroscience company Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, paying $38 per share — a 37% premium to the NASDAQ closing price. Centessa shareholders will also receive contingent value rights of $9 per share, worth up to $1.5 billion, subject to regulatory milestones for lead candidate cleminorexton, a treatment for excessive daytime sleepiness and narcolepsy. The acquisition adds to a string of high-value agreements Lilly has pursued in early 2026, including a $2.4 billion deal with Orna Therapeutics and an $8.8 billion collaboration with Innovent.

Read at HealthCare MEA →

NEWS · M&A

EXTERNAL →

M&APrivate Equity

UK Healthcare M&A Reaches 280 Deals in 2025 — Outperforming Wider Market by 10–15 Percentage Points

Source: Heligan Group via Home Care Insight · February 2026

UK healthcare M&A activity totalled 280 announced or completed deals in 2025 — broadly flat year-on-year — while dealmaking across most UK sectors declined by 10–15%, according to Heligan Group's annual review. Health and Social Care accounted for 47% of deal volume. Strategic buyers represented 83% of transactions. Inbound transactions accounted for 24% of activity, with the US the largest source of cross-border investment. PE remained active on bolt-ons despite entering 2026 with significant dry powder. The sector's defensive and structurally supported characteristics drove continued outperformance against the wider M&A market.

Read at Home Care Insight →

NEWS · HEALTHCARE REAL ESTATE

EXTERNAL →

Healthcare Real EstateM&A

Royal London Asset Management Launches £1bn Healthcare REIT to Scale UK Care Infrastructure Investment

Source: Investors in Healthcare / Real Assets · October 2025

Royal London Asset Management Property has launched a UK healthcare real estate investment trust, which it plans to grow to £1 billion in value. The firm has already deployed £350 million in healthcare property assets since early 2022, and in mid-2025 brought sector specialists Shoreline Partners in-house as part of its £1 billion ambition. RLAM Property said the REIT structure will provide a more competitive and internationally recognised investment vehicle to attract third-party capital, execute forward funding deals and acquire corporate entities. The launch reflects growing domestic investor appetite for UK healthcare real estate alongside the dominant US REIT capital that deployed £12 billion+ into the sector in 2025.

Read at Investors in Healthcare →

NEWS · MEDTECH

EXTERNAL →

MedTechM&A

Smith & Nephew Acquires Integrity Orthopaedics for £450m in Q1 2026 Strategic Bolt-On

Source: Business Sale Report / Manufacturing Chemist · Q1 2026

FTSE 100 medical technology company Smith & Nephew completed a £450 million takeover of Integrity Orthopaedics in Q1 2026, reinforcing its orthopaedics portfolio through targeted inorganic growth. The acquisition is part of Smith & Nephew's ongoing programme of bolt-on deals to strengthen its position in high-growth orthopaedic sub-segments. The deal took place alongside GSK's £1.7 billion acquisition of RAPT Therapeutics and Sovereign Capital Partners' acquisition of Apollo Home Healthcare as the three most significant UK-connected healthcare transactions of Q1 2026, according to the Heligan Group quarterly review.

Read at Manufacturing Chemist →

NEWS · HCIT

EXTERNAL →

HCITDiagnostics

NHS Shared Business Services Launches £900m Healthcare AI Solutions Procurement Framework

Source: Digital Health News · May 2026

NHS Shared Business Services launched a £900 million framework agreement on 11 May 2026 to support procurement of AI technologies across the NHS and wider public sector. The Healthcare AI Solutions framework covers diagnostics, predictive analytics, operational efficiency, robotics and consultancy services, providing NHS organisations with a national procurement route for AI technologies. The framework's launch — significantly expanded in value following supplier consultations — signals the scale of NHS commitment to AI-enabled healthcare delivery under the government's 10 Year Health Plan.

Read at Digital Health →

NEWS · ANIMAL HEALTH

EXTERNAL →

Animal HealthVenture Capital

Animalcare Group Reports 20% Revenue Growth in 2025 Following Randlab Acquisition and Asia-Pacific Expansion

Source: Hargreaves Lansdown / Sharecast · January 2026

AIM-listed Animalcare Group reported revenue growth of 20% year-on-year to £89.1 million in 2025, reflecting successful integration of the Randlab acquisition alongside continued organic growth and new product development. The veterinary medicines group strengthened its Asia-Pacific presence through a 25% strategic equity investment in Australia-based InVetro, and signed a licence agreement with 272Bio to access half-life extension technology for equine biologics. Animalcare said it plans to invest approximately 5% of revenue annually in innovation from 2026 — with five key R&D projects currently in progress including a VHH NGF antibody programme for companion animal pain.

Read at Hargreaves Lansdown →

NEWS · DIAGNOSTICS

EXTERNAL →

DiagnosticsHCIT

UK Government Invests £28.1m in NHS AI Diagnostics — Including £20m to Roll Out AI Chest X-Ray to Every NHS Trust by 2029

Source: NIHR / DHSC · June 2026

The UK government has announced £28.1 million of investment in NHS AI diagnostic tools, including £20 million to extend AI-assisted chest X-ray technology to every NHS Trust in England by 2029. The software — which helps radiologists identify abnormalities more quickly — is already deployed in around half of NHS Trusts and has supported faster diagnoses for more than four million patients. An additional £8.1 million through NIHR will fund development and evaluation of six new AI and digital health technologies across 12 NHS Trusts, covering CT scans, ECGs and X-rays for conditions including heart failure, stroke, lung infections and lung cancer.

Read at Innovation News Network →

Stay Ahead of UK Healthcare Investment News

Subscribe free for M&A deals, funding rounds and market intelligence across all nine UK healthcare sectors — including alternative healthcare investments, specialty pharma and medical cannabis.

Subscribe Free →